Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms.
2017 Standout
A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty*
2000
Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation)
2003
Simultaneous comparison of multiple treatments: combining direct and indirect evidence
2005
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
2001
Heparin-Induced Thrombocytopenia
2000
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Emotion-regulation strategies across psychopathology: A meta-analytic review
2009 Standout
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
2002
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery
2003
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
2001
Prevention of venous thromboembolism
2001
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Procedural memory stimulation in Alzheimer's disease: impact of a training programme
1997
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>
2002
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial
2002
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study
2002
Antithrombotic Therapy for Venous Thromboembolic Disease
1998
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Hepatitis B virus infection
2009 Standout
Criterion-Related Validity of the Diagnostic Criteria for Psychosomatic Research for Alexithymia in Patients with Functional Gastrointestinal Disorders
2001
Are alexithymia, depression, and anxiety distinct constructs in affective disorders?
2000
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients
2003
Duration of Venous Thromboembolism Prophylaxis After Surgery
2003
Thromboprophylaxis with 60 mg Enoxaparin Is Safe in Hip Trauma Surgery
2001
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Bivalent direct thrombin inhibitors: hirudin and bivalirudin
2004
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Acute Stressors and Cortisol Responses: A Theoretical Integration and Synthesis of Laboratory Research.
2004 Standout
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery
2007
Sociodemographic correlates of alexithymia
1998
The Assessment of Deep Vein Thromboses for Therapeutic Trials
2003
Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies
2007
Heparin-Induced Thrombocytopenia
2006 Standout
Acne vulgaris
2011 Standout
Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?
2002
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
2003
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients
2000
PROPHYLAXIS OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM
1998
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Prevention of Venous Thromboembolism
2004 Standout
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Alzheimer's disease
2006 Standout
Pre-eclampsia
2010 Standout
Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement
2001
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
2005
The 20-Item Toronto Alexithymia Scale
2003 Standout
A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II
2000
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points
2004
Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement
2002
The origins and functions of dendritic cells and macrophages in the skin
2014
Prevention of Venous Thromboembolism
2008 Standout
The global impact of vaccination against hepatitis B: A historical overview
2008
Genetics and Genomics of Pulmonary Arterial Hypertension
2013
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
2003
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Alzheimer's Disease
2004 Standout
Cognitive Stimulation in Patients with Dementia: Randomized Controlled Trial
2013 Standout
Cardiovascular reactivity of mitral valve prolapse patients during experimental stress exposure: evidence for a functional nature of cardiovascular symptoms
1996
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison
2002
Preoperative vs Postoperative Initiation of Low-Molecular-Weight Heparin Prophylaxis Against Venous Thromboembolism in Patients Undergoing Elective Hip Replacement
1999
Hepatocellular Carcinoma
2011 Standout
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Mild cognitive impairment as a diagnostic entity
2004 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
2004
Prevention of Venous Thromboembolism
1998
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
2001
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2018
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
2005 Standout
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
The emerging role of computational design in peptide macrocycle drug discovery
2020
Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials
1997
Ultraviolet B–Induced Maturation of CD11b-Type Langerin− Dendritic Cells Controls the Expansion of Foxp3+ Regulatory T Cells in the Skin
2017 StandoutNobel
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery
2002 StandoutNobel
Natural History of Venous Thromboembolism
2003
Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
2005
Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels
2017 StandoutNobel
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
The link between emotional competence and well-being: a longitudinal study
2006
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance
2000
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.
2001
Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance
2003
Wound Healing: A Cellular Perspective
2018 Standout
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
2002
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Physical Activity and Public Health in Older Adults
2007 Standout
Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated With R-Hirudin
1999
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
2012 Standout
Assessment of alexithymia : self-report and observer-rated measures
2000
Low Molecular Weight Heparin Decreases Proximal and Distal Deep Venous Thrombosis Following Total Knee Arthroplasty
1998
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.
1999
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
Acne: more than skin deep
2006
Prevention of deep-vein thrombosis after total hip and knee replacement
2004
Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension
2010
Prevention of Deep Vein Thrombosis after Hip Replacement
1999
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
Regional Anesthesia in the Anticoagulated Patient
2003
Works of Doris Bach being referenced
Validierung der deutschen Version der 20-Item Toronto-Alexithymie-Skala bei Normalpersonen und psychiatrischen Patienten.
1996
Acute Hemodynamic Effects of Single‐Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS‐1 Study
2009
Psychiatric and Psychometric Issues in Acné excoriée
1993
Alexithymia in Somatof orm Disorder and Somatic Disease; A Comparative Study
1996
Alexithymia and somatization: Relationship to DSM-III-R diagnoses
1994
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine
2006
Predictive Value of Alexithymia: A Prospective Study in Somatizing Patients
1995
Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*
1997
Reactivating Occupational Therapy: A Method to improve Cognitive Performance in Geriatric Patients
1995
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)
2011
A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement
1997
Transcutaneous vaccination via laser microporation
2012
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393
1996
Independency of Alexithymia and Somatization
1996
[Validation of the German version of the 20-item Toronto Alexithymia Scale in normal persons and psychiatric patients].
1996
Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
1993